



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



HLA-DP β 1 siRNA (h2): sc-43929

BACKGROUND

Major histocompatibility complex (MHC) molecules, also designated human leukocyte antigen (HLA) molecules, are cell-surface receptors that bind foreign peptides and present them to T lymphocytes. MHC class I molecules consist of two polypeptide chains, an α or heavy chain and β -2-Microglobulin, a non-covalently associated protein. Cytotoxic T lymphocytes bind antigenic peptides presented by MHC class I molecules. Antigens that bind to MHC class I molecules are typically eight to ten residues in length and are stabilized in a peptide binding groove. MHC class II molecules are encoded by polymorphic MHC genes and consist of a non-covalent complex of an α and β chain. Helper T lymphocytes bind antigenic peptides presented by MHC class II molecules. MHC class II molecules bind 13-18 amino acid antigenic peptides. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM and -DO molecules regulate binding of exogenous peptides to class II molecules (HLA-DR) by sustaining a conformation that favors peptide exchange. The differential structural properties of MHC class I and class II molecules account for their respective roles in activating different populations of T lymphocytes.

REFERENCES

1. Murphy, D.B., Lo, D., Rath, S., Brinster, R.L., Flavell, R.A., Slanetz, A. and Janeway, C.A., Jr. 1989. A novel MHC class II epitope expressed in thymic medulla but not cortex. *Nature* 338: 765-768.
2. Rudensky, A.Y., Rath, S., Preston-Hurlburt, P., Murphy, D.B. and Janeway, C.A., Jr. 1991. On the complexity of self. *Nature* 353: 660-662.
3. Agger, R., Petersen, M.S., Toldbold, H.E., Holtz, S., Dagnaes-Hansen, F., Johnsen, B.W., Bolund, L. and Hokland, M. 2000. Characterization of murine dendritic cells derived from adherent blood mononuclear cells *in vitro*. *Scand. J. Immunol.* 52: 138-147.
4. Viret, C. and Janeway, C.A., Jr. 2000. Functional and phenotypic evidence for presentation of E a 52-68 structurally related self-peptides in I-E α -deficient mice. *J. Immunol.* 164: 4627-4634.
5. Fischer, G.F. and Mayr, W.R. 2001. Molecular genetics of the HLA complex. *Wien. Klin. Wochenschr.* 113: 814-824.
6. Günther, E. and Walter, L. 2001. The major histocompatibility complex of the rat (*Rattus norvegicus*). *Immunogenetics* 53: 520-542.
7. Little, A.M. and Parham, P. 2001. Polymorphism and evolution of HLA class I and II genes and molecules. *Rev. Immunogenet.* 1: 105-123.
8. Van Kaer, L. 2001. Accessory proteins that control the assembly of MHC molecules with peptides. *Immunol. Res.* 23: 205-214.
9. Zaliauskene, L., Kang, S., Sparks, K., Zinn, K.R., Schwiebert, L.M., Weaver, C.T. and Collawn, J.F. 2002. Enhancement of MHC class II-restricted responses by receptor-mediated uptake of peptide antigens. *J. Immunol.* 169: 2337-2345.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: HLA-DPB1 (human) mapping to 6p21.32.

PRODUCT

HLA-DP β 1 siRNA (h2) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see HLA-DP β 1 shRNA Plasmid (h2): sc-43929-SH and HLA-DP β 1 shRNA (h2) Lentiviral Particles: sc-43929-V as alternate gene silencing products.

For independent verification of HLA-DP β 1 (h2) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-43929A, sc-43929B and sc-43929C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

HLA-DP β 1 siRNA (h2) is recommended for the inhibition of HLA-DP β 1 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor HLA-DP β 1 gene expression knockdown using RT-PCR Primer: HLA-DP β 1 (h2)-PR: sc-43929-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.